Exelixis drops tissue factor-targeting ADC after deciding it's no match for Tivdak

Exelixis is giving up on its tissue factor (TF)-targeting antibody-drug conjugate after concluding the candidate was unlikely to best Pfizer and Genmab’s Tivdak.